Clinical Trial Highlights

Core P&L Strong sales growth and significant investment for growth Γ €m H1 2023 H1 2022 Change Total Sales 1,536.6 1,433.7 7.2% Other revenue 86.5 64.2 34.8% Total sales Limited impact of currencies Other revenue Cost of goods sold (269.9) (242.1) 11.5% Favorable impact from license rights to Onivyde Gross Profit 1,353.3 1,255.8 7.8% % of total sales 88.1% 87.6% 0.5pts R&D expenses % of total sales SG&A expenses (290.2) (207.2) 40.1% 18.9% 14.5% 4.4pts Cost of goods sold Adverse mix of royalties paid R&D expenses Investment from pipeline (552.6) (487.3) 13.4% assets of Epizyme & Albireo % of total sales 36.0% 34.7% 13.0pts SG&A expenses Commercial investment for Other operating income and expenses 12.7 6.5 94.9% Core Operating Income 523.2 568.0 -7.9% growth including Tazverik & Bylvay launch activity % of total sales 34.0% 39.6% -5.6pts IPSEN Innovation for patient care All growth rates are at actual exchange rates. 11

View entire presentation